title: Postmortem neuropathological features secondary to boron neutron capture therapy for glioblastoma multiforme.
abstract: This postmortem study of 12 patients with glioblastoma multiforme (GBM) treated with boron neutron capture therapy (BNCT) employing an epithermal neutron beam and p-boronophenylalanine describes the neuropathological findings in patients receiving a relatively high radiation dose to the tumor, but a relatively low radiation dose to the normal brain. In addition to a standardized neuropathology panel of sections, we used individual treatment dosimetry maps to select sections along the projected maximum radiation beam pathway. We found that the normal neuroparenchyma exposed to the highest radiation dose exhibited a single instance of radiation-induced focal venular fibrinoid necrosis and a single instance of multifocal demyelination. Semiquantitative analysis of pretreatment neurosurgical and postmortem tumor samples revealed only two radiation ascribed histopathological findings to be particular to therapy, fibrinoid necrosis and vascular hyalinization. In this relatively small series of cases we found an unexpectedly high frequency of cases (3 of 12) with neurodegenerative histopathology (Lewy bodies, neurofibrillary tangles, and neuritic senile plaques), which appeared, by distribution, to be independent of the radiation beam. Two of these patients were over 70 yr of age. One was only 41. Our findings suggest an acceptable radiation-induced level of neurotoxicity at the lower doses employed, but raise the possibility of unexpected boron neurodegenerative toxicity.
authors.affiliation: Department of Pathology, State University of New York, Stony Brook 11794-7025, USA.
authors.forename: T
authors.initials: T
authors.lastname: Aziz
authors.forename: N S
authors.initials: NS
authors.lastname: Peress
authors.forename: A
authors.initials: A
authors.lastname: Diaz
authors.forename: J
authors.initials: J
authors.lastname: Capala
authors.forename: A
authors.initials: A
authors.lastname: Chanana
mesh_terms: D000328:Adult; D000368:Aged; D001896:Boron Compounds / Q000627:therapeutic use; D016754:Boron Neutron Capture Therapy; D001921:Brain / Q000473:pathology; D001932:Brain Neoplasms / Q000473:pathology* / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005909:Glioblastoma / Q000473:pathology* / Q000532:radiotherapy*; D006801:Humans; D016631:Lewy Bodies / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009410:Nerve Degeneration / Q000473:pathology; D016874:Neurofibrillary Tangles / Q000473:pathology; D009474:Neurons / Q000528:radiation effects; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use
chemical_list: D001896:Boron Compounds; D011838:Radiation-Sensitizing Agents; D010649:Phenylalanine; C033685:4-boronophenylalanine